RAP 0.00% 20.5¢ resapp health limited

Ann: Trading Halt, page-7

  1. 4,855 Posts.
    lightbulb Created with Sketch. 2375
    Also... this seems strongly at odds with the last appendix 4C. The company stated:

    Strong balance sheet to advance ResApp through commercialisation. The company held
    cash of $3.9 million as of December 31, 2019. ResApp received a $1.8 million R&D tax
    incentive cash rebate from its FY2019 R&D spend during the quarter. A significant proportion
    of R&D spend for the current financial year will also be eligible for the R&D tax incentive.

    The company claimed to have sufficient funds to "advance ResApp through commercialisation". Yet now we suddenly need cash. I'm feeling just a little bit misled right now. And that has legal implications for the directors.
    Last edited by TerribleTadpole: 19/02/20
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.